About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDNANCT04568109

Effect of Cognitive-behavior Therapy on Fear Responses to Body Symptoms in Patients With Panic Disorder

The present study aims to investigate a potential mechanism of successful CBT for panic disorder, i.e., the reduction of excessive anxious apprehension and fear responses to panic-related body symptom...

Lead sponsor: Philipps University Marburg•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Philipps University Marburg

Collaborators

German Federal Ministry of Education and Research

Changes in fear responses to body symptoms in the course of CBT are investigated in patients with PD by applying a highly standardized hyperventilation task (provoking panic-related body symptoms) prior to and after a manualized CBT or a waiting period. Activation of the brain's fear network (defensive activation) is indexed by the potentiation of the startle eyeblink response.

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•current primary diagnosis of panic disorder (with or without agoraphobia) as defined by the criteria of the diagnostic and statistical manual, fourth revision/text revision (DSM-IV-TR) (determined using the Composite International Diagnostic Interview and verified by a certified psychotherapist)
•age 18 - 65 years

Exclusion Criteria

•current suicidal intent
•any psychotic or bipolar disorder
•borderline personality disorder
•a medical condition that could explain patients' symptoms
•physical contradictions regarding application of exposure-based CBT (e.g., neurological disease)
•Patients has to be on a stable psychopharmacological medication schedule prior to study entry for at least 12 weeks
•Intake of benzodiazepines

Related studies

A Transdiagnostic, Self-guided Internet Intervention ("Velibra") for Waitlist Patients With Anxiety Disorders

NCT04793828 · Panic Disorder With Agoraphobia, Panic Disorder Without Agoraphobia, and more

Active Not RecruitingNA

Evaluation of Family-Based Behavioral Treatments for Youth With Anxiety and Obsessive-Compulsive Disorder

NCT05967468 · Obsessive-Compulsive Disorder in Children, Anxiety Disorder of Childhood, and more

Mechanisms of Treatment Change in Panic Disorder and Agoraphobia

NCT03547180 · Panic Disorder With Agoraphobia

Construction of a Questionnaire on Panic Disorder and Agoraphobia

NCT03885453 · Panic Disorder, Panic Disorder With Agoraphobia, and more

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: September 29, 2020Terms

Trial snapshot

StatusCOMPLETED

PhaseNA

Enrollment58

Start dateFeb 2010

Last updatedSep 29, 2020

Condition

Panic Disorder With Agoraphobia Panic Disorder Without Agoraphobia

Locations shown

University of Greifswald

Greifswald

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 29, 2020Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions